US 11,702,478 B2
Agonistic CD40 antibodies
Stephan Fischer, Weilheim (DE); and Karsten Beckmann, Vaterstetten (DE)
Assigned to MAB DISCOVERY GMBH, Neuried (DE)
Appl. No. 16/648,731
Filed by MAB DISCOVERY GMBH, Neuried (DE)
PCT Filed Sep. 19, 2018, PCT No. PCT/EP2018/075388
§ 371(c)(1), (2) Date Mar. 19, 2020,
PCT Pub. No. WO2019/057792, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 17191974 (EP), filed on Sep. 19, 2017.
Prior Publication US 2020/0239583 A1, Jul. 30, 2020
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01)] 13 Claims
OG exemplary drawing
 
1. An agonistic monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds to the human CD40 receptor and is capable of inducing CD40 signaling independent of Fcγ mediated CD40 receptor crosslinking;
wherein the antibody comprises a variable heavy (VH) region that is at least 85% identical to SEQ ID NO: 5 and comprises CDR regions CDR1H, CDR2H, and CDR3H as set forth in SEQ ID NO: 33, SEQ ID NO: 47, and SEQ ID NO: 61, respectively; and
wherein the antibody comprises a variable light (VL) region that is at least 85% identical to SEQ ID NO: 19 and comprises CDR regions CDR1L, CDR2L, and CDR3L as set forth in SEQ ID NO: 75, SEQ ID NO: 89, and SEQ ID NO: 103, respectively.